Invesco

Matalan

Seed Round in 2025

Matalan is a British fashion and homeware retailer based in Knowsley, United Kingdom.

Asia Dragon Trust

Acquisition in 2025

Asia Dragon Trust is an investment trust based in the United Kingdom, dedicated to providing investors with access to reputable businesses in the Far East, excluding Japan and Australasia. The primary objective of the trust is to achieve long-term capital growth through investments in the stock market, focusing on large companies deemed attractively priced. The trust maintains a diversified portfolio across various sectors, including Aerospace & Defence, Banking, Automobiles, Construction Materials, Industrial Conglomerates, Real Estate Management and Development, and Wireless Telecommunications Services. Performance is measured against the MSCI All Country Asia (ex-Japan) index, allowing the trust to evaluate its investment effectiveness in the region.

Caredoc

Venture Round in 2024

Caredoc is a platform focused on elderly care, designed to address the challenges faced by families seeking reliable information about care facilities and providers. Many consumers struggle to find accurate details online or rely on unverified recommendations, while care service providers often face difficulties in reaching potential clients. Caredoc offers a solution by providing verified information on various elderly care services through a user-friendly mobile interface. The platform includes features such as quick matching functions and detailed profiles of caretakers, hospitals, and doctors, complete with reviews and ratings. This enables families to efficiently search for and select appropriate care options tailored to their specific needs.

Franklin Energy Services

Private Equity Round in 2024

Franklin Energy Services, LLC is a company that specializes in designing and implementing customized energy efficiency programs for utilities, municipalities, and government bodies. Founded in 1989 and based in Port Washington, Wisconsin, it serves a diverse range of sectors including residential, multifamily, education, small businesses, agriculture, and commercial and industrial markets. The company provides various services such as trade ally management, rebate processing, engineering solutions, marketing, and customer care. Franklin Energy is recognized for its expertise in program administration and implementation, focusing on solutions that promote the efficient consumption of electricity and natural gas. This helps clients reduce energy consumption and achieve lower operating and maintenance costs. Franklin Energy Services was previously known as Schueller Energy Consultants before changing its name in January 1994.

Mynd

Venture Round in 2023

Mynd is a technology-driven property management firm that specializes in managing single-family rental properties. The company is dedicated to helping property owners optimize their real estate investments through a comprehensive suite of services, which includes property marketing, tenant screening, rent collection, property maintenance, and accounting. By focusing on the rental sector, Mynd aims to simplify the property management process, reducing the everyday burdens faced by landlords while maximizing their investment returns. The firm leverages technology and data analytics to improve property performance and ensure effective communication with clients. Property owners benefit from access to financial reports and real-time updates, enabling them to make informed decisions about their investments through Mynd's digital platforms.

Flowcarbon

Series A in 2022

Flowcarbon, founded in 2021 and headquartered in New York, specializes in carbon token technology aimed at accelerating decarbonization through nature-based climate initiatives. The company provides token-backed carbon credits that are directly linked to premium renewable energy projects, ensuring benefits that prioritize climate mitigation, local and indigenous communities, and biodiversity protection. Flowcarbon's expertise in investment banking, project finance, and financial markets allows it to offer innovative capital solutions tailored for businesses in infrastructure and decarbonization sectors. By focusing on high-quality project development and credit portfolio services, Flowcarbon enables companies to effectively offset their carbon emissions and contribute to sustainable environmental practices.

GeNeuro

Post in 2022

GeNeuro is a biotechnology company based in Plan-Les-Ouates, Switzerland, specializing in the development of therapeutic drugs for diseases linked to pathogenic proteins originating from human endogenous retroviruses. The company primarily targets nervous system disorders, including multiple sclerosis and schizophrenia. Its lead product, GNbAC1, is a therapeutic monoclonal antibody designed to treat multiple sclerosis, while temelimab is another candidate that neutralizes a pathogenic protein from the HERV-W family. Additionally, GeNeuro is engaged in developing diagnostic tests to measure multiple sclerosis-associated retrovirus-ENV proteins in patients. Founded in 2006, the company is committed to addressing the underlying factors that drive the progression of neurodegenerative and autoimmune diseases.

Copper Banking

Series A in 2022

Copper Banking is a financial education platform designed to empower teenagers with financial literacy and banking services. By offering a user-friendly app and debit card, Copper enables teens to manage their money effectively, gaining hands-on experience that traditional banks often overlook. The platform facilitates money transfers, direct deposits, and payments while fostering a connection between parents and teens regarding financial decisions. Additionally, Copper provides exclusive content crafted by financial literacy experts, equipping users with valuable advice and tips to enhance their understanding of personal finance and help them take control of their financial futures. Through these features, Copper seeks to instill responsible financial habits in young users.

Capchase

Series B in 2022

Capchase Inc. is a fintech company that specializes in providing financing solutions for Software as a Service (SaaS) businesses by unlocking cash tied up in future monthly payments. Founded in 2020 and based in New York, Capchase utilizes proprietary underwriting algorithms to evaluate the quality of contracts and extend lines of debt to its clients. Its platform allows SaaS companies to receive upfront payments for their services while offering flexible repayment options, such as monthly or quarterly payments. This approach enables clients to accelerate their growth without incurring dilution or relying on costly financing methods.

Swiggy

Venture Round in 2022

Swiggy is an on-demand food delivery platform that connects customers with local restaurants, allowing them to order meals conveniently through a user-friendly app. The platform provides a comprehensive listing of nearby restaurants and their menus, enabling users to place orders and track deliveries in real-time. In addition to food delivery, Swiggy has expanded its services to include the pickup and drop-off of various items, such as laundry and documents, catering to both individual and business clients. By offering timely deliveries and promotional discounts, Swiggy aims to enhance the customer experience and ensure that meals are delivered fresh and promptly.

Hum Capital

Series A in 2021

Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.

Pine Labs

Venture Round in 2021

Pine Labs operates a merchant platform that provides technology and financial solutions aimed at enhancing revenue for merchants while minimizing costs, complexity, and risk. The company connects financial institutions and consumer brands, facilitating both offline and online retail transactions. Pine Labs powers over 350,000 point-of-sale terminals across more than 3,700 cities and towns in India and Malaysia, serving over 100,000 merchants in various sectors, including electronics, food and beverage, and fashion. Its platform also offers customer insights to drive targeted sales and streamline payment acceptance through features like easy monthly installments (EMI) across multiple banks and product categories. Additionally, Pine Labs collaborates with 15 major banks, seven financial institutions, and more than 100 brands to enhance the retail experience for both merchants and consumers.

Aumni

Series B in 2021

Aumni is a data-driven investment analytics platform based in the United States, specifically designed for private capital markets, including venture funds, family offices, university endowments, and corporate venture firms. Founded by former corporate attorneys Tony Lewis and Kelsey Chase in Salt Lake City, Aumni utilizes a combination of artificial intelligence and human expertise to extract and analyze critical deal data from complex legal agreements. The platform provides strategic insights related to the economic positions and legal rights of investors by converting intricate deal data into a clear, complete, and accurate dataset. Additionally, Aumni conducts audits and analyses of transactions to ensure the completeness and accuracy of documentation, thereby enabling investors and venture firms to make informed decisions based on a comprehensive understanding of their investments. The company has successfully analyzed a vast array of private capital data, representing investors with over $1 trillion in assets under management.

Abogen Biosciences

Series C in 2021

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Mynd

Venture Round in 2021

Mynd is a technology-driven property management firm that specializes in managing single-family rental properties. The company is dedicated to helping property owners optimize their real estate investments through a comprehensive suite of services, which includes property marketing, tenant screening, rent collection, property maintenance, and accounting. By focusing on the rental sector, Mynd aims to simplify the property management process, reducing the everyday burdens faced by landlords while maximizing their investment returns. The firm leverages technology and data analytics to improve property performance and ensure effective communication with clients. Property owners benefit from access to financial reports and real-time updates, enabling them to make informed decisions about their investments through Mynd's digital platforms.

Brii Biosciences

Series C in 2021

Brii Biosciences Limited is a biotechnology company focused on the research, development, and commercialization of innovative medicines for chronic and infectious diseases, including hepatitis B virus (HBV), human immunodeficiency virus (HIV), and multi-drug resistant infections. Founded in 2018, the company is headquartered in Durham, North Carolina, with additional offices in Shanghai, Beijing, and San Francisco. Brii Biosciences aims to enhance healthcare outcomes for patients in China by leveraging advanced technology and data. The company has established strategic partnerships with organizations such as AliHealth and Vir to further its mission. With a robust pipeline consisting of over 10 product candidates, Brii Biosciences is dedicated to addressing significant public health challenges both in China and globally, focusing on delivering better treatments and cures for life-threatening diseases.

Godrej Garden City

Post in 2021

Godrej Properties brings the Godrej Group philosophy of innovation and excellence to the real estate industry. Each Godrej Properties development combines a 119-year legacy of excellence and trust with a commitment to cutting-edge design and technology. Godrej Properties is currently developing residential, commercial and township projects spread across 10.3 million square meters (111 million square feet) in 12 cities.

Nubank

Series G in 2021

Nubank is a prominent digital bank revolutionizing finance with its customer-centric approach. It provides a variety of services, including credit cards, personal loans, and digital payments, all accessible through a simple mobile app. Known for transparency, ease of use, and low fees, Nubank aims to empower users with innovative solutions for better financial management.

Expert.ai

Post in 2020

Expert.ai is a developer of enterprise natural language processing technologies that focuses on transforming language-intensive processes into actionable insights. The company's platform combines symbolic human-like understanding with machine learning, enabling organizations to enhance decision-making and streamline operations. Expert.ai offers a range of solutions, including Cogito Discover, which utilizes artificial intelligence for analytics, extraction, and categorization of text across various formats, thus facilitating automation. Additionally, the Clinical Research Navigator assists biomedical clients in advancing research into therapies for infectious diseases. The company provides its services through on-premise, private, and public cloud offerings, catering to diverse industries such as insurance, banking, publishing, defense, and life sciences.

Clarksons

Post in 2019

Clarksons offers its diverse and growing client base an unrivalled range of shipbroking services, sector research, on-hand logistical support and full investment banking capabilities in all key shipping and offshore sectors.

intelliflo redblack

Acquisition in 2019

Intelliflo redblack is a developer of intuitive software designed to support registered investment advisors (RIAs) and family offices in managing their trading and rebalancing needs. The platform offers a comprehensive solution that includes portfolio monitoring, pre-trade and post-trade compliance, and order management, all within a single, scalable system. This capability allows firms to enhance client value while achieving growth and operational efficiency. By integrating seamlessly with existing technology infrastructures, intelliflo redblack empowers advisors to deliver personalized services with superior precision, ultimately helping them navigate the complexities of investment management more effectively.

Grab

Series H in 2019

Grab Holdings Inc. is a prominent online-to-offline service provider based in Singapore, focusing on mobile technology solutions for transportation across Southeast Asia. Founded in 2012 by Anthony Tan and Tan Hooi Lng, Grab integrates various transportation services through its platform, which includes offerings such as GrabTaxi, GrabCar, GrabHitch, GrabShare, GrabCoach, GrabShuttle, GrabShuttle Plus, GrabFamily, JustGrab, GrabNow, and GrabRental. The company operates in multiple countries, including Singapore, Indonesia, the Philippines, Malaysia, Thailand, Vietnam, and Myanmar. In addition to its headquarters in Singapore, Grab has offices in Seattle, Beijing, Bangalore, Jakarta, and Vietnam, further extending its reach and capabilities within the region.

Evofem Biosciences

Post in 2019

Evofem Biosciences is a biopharmaceutical company based in San Diego, California, focused on addressing unmet needs in women's sexual and reproductive health. The company has developed Phexxi, the first and only hormone-free prescription vaginal gel approved in the United States for pregnancy prevention. In addition to Phexxi, Evofem is also working on EVO100, a vaginal pH regulator aimed at preventing the urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Through its innovative products, Evofem Biosciences aims to enhance reproductive health care options for women.

OppenheimerFunds

Acquisition in 2018

OppenheimerFunds, Inc. is a privately owned investment manager established in 1959, based in New York City with additional offices in Rochester, London, Salt Lake City, and Centennial. The firm provides a comprehensive range of investment services, including asset management, retirement planning, mutual funds, separately managed accounts, and investment management for institutions. It serves a diverse clientele comprising financial advisors, individual investors, corporations, and endowments. OppenheimerFunds focuses on launching and managing equity, fixed income, balanced, multi-asset mutual funds, and hedge funds, employing fundamental analysis and external research to guide its investment strategies. The firm invests across public equity, fixed income, and alternative markets globally. As of May 24, 2019, OppenheimerFunds operates as a subsidiary of Invesco Ltd.

Intelliflo

Acquisition in 2018

Intelliflo Ltd. is a provider of web-based business management software tailored for the financial services sector in the United Kingdom. Founded in 2004 and based in Kingston-upon-Thames, the company offers its flagship product, Intelligent Office, which serves a diverse clientele, including financial advisers, mortgage advisers, and service providers. This platform encompasses a wide range of features such as client management, financial planning, task management, compliance, and document management, enhancing operational efficiency for its users. Additionally, Intelliflo provides tools for investment research and portfolio monitoring through its FE Analytics module. The company aims to simplify the advisory experience by leveraging open software architectures and continuously evolving its technology to meet the needs of over 30,000 financial professionals worldwide, thereby supporting over three million end-investors. Through its comprehensive solutions, Intelliflo seeks to widen access to financial advice and improve the overall efficiency of financial advisory practices.

Alfred

Series B in 2018

Founded in 2014 by Marcela Sapone and Jessica Beck, Alfred is the largest and most advanced residential management platform. Since its inception, Alfred has focused on providing a resident-first experience. With an unparalleled knowledge of what residents want and technology that boosts income and efficiency for owners and operators, Alfred provides a single stop that elevates the rental ecosystem for all involved. Named by Fast Company as one of the Top 50 Most Innovative Companies, Alfred’s AOS technology drives lower operating costs and higher returns for property owners and operators. Through strategic partnerships with international real-estate owners and operators such as Hines, Related, RXR, Greystar, Invesco, Brookfield and J.P. Morgan, With RKW, Alfred’s portfolio now extends to more than 300,000 residents in 44 cities across the U.S. and Canada and has planned expansions in Europe, Israel and Asia.

T She Dingzhi

Series A in 2018

T She Dingzhi offers a platform for clothes design. Their business enables additional, fully-customizable t-shirts, hoodies, and sweaters to its clients. Through responsible, managed services, subscription cultural apparel, and other means, they are dedicated to assisting businesses in improving their services. It adapts and pursues accuracy and exquisite, repeatedly setting the bar for the sector.

Lamellar Biomedical

Series C in 2017

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that leverage mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic product designed to replicate the functions of lamellar bodies, primarily targeting respiratory diseases such as cystic fibrosis, as well as conditions like dry eye disease and radiotherapy-induced xerostomia. Established in June 2007, Lamellar Biomedical acquired the intellectual property rights to this innovative technology, which aims to improve treatment outcomes through anti-infective properties that enhance antibiotic efficacy and facilitate the delivery of genetic material for pulmonary disease therapies. The company's efforts are directed towards providing transformative solutions for complex and rare respiratory conditions.

Source ETF

Acquisition in 2017

Source is uniquely positioned to deliver highly liquid products that respond to the challenges and opportunities of the market They partner with some of the world’s largest investment houses and asset managers to create products that either offer exposure to new opportunities in the market or deliver existing strategies more effectively. They work together to ensure all of their products are efficient and transparent. On top of this, they work closely with some of the most well respected trading houses in Europe to ensure that their products are also priced as fairly as possible and are tradable throughout the day. Source is a global investment firm and one of the fastest growing European providers of exchange traded products (ETPs) By focusing on the ever-evolving needs of investors, they have grown assets under management to more than $19 billion (as at 30 July 2014) since their launch in April 2009, and during this time investors have traded more than $575 billion of Source’s products. They offer investors an efficient and transparent way to invest in equities, fixed income and commodities, as well as some alternative asset classes. Their ETPs are open-ended and domiciled in Dublin.

Glide Pharmaceutical

Venture Round in 2017

Glide Pharmaceutical Technologies is a clinical stage development company that specializes in the creation of solid dose formulations for therapeutics and vaccines. The company is known for its innovative solid dose injector system, which aims to enhance patient compliance in self-administering long-term therapies. Glide's product pipeline features formulations for various medications, including octreotide, teriparatide, and vaccines for anthrax and influenza. The company's focus on needle-free injection methods seeks to improve the treatment experience for both patients and healthcare providers. Formerly known as Caretek Medical, Glide Pharmaceutical is dedicated to advancing healthcare through its unique delivery systems.

Vedanta Biosciences

Venture Round in 2016

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Nexeon

Private Equity Round in 2016

Nexeon Limited is a developer and manufacturer of advanced silicon-based anode materials for rechargeable lithium-ion batteries. Founded in 2006 and headquartered in Abingdon, United Kingdom, with an additional office in Yokohama, Japan, the company focuses on creating innovative battery materials that enhance energy density and capacity. These improvements allow for the production of lighter, more powerful batteries that can support a variety of applications, including consumer electronics, electric vehicles, sustainable energy, aerospace, medical, and defense industries. By enabling longer battery life and faster charging times, Nexeon's technology plays a crucial role in advancing sustainable energy solutions and supporting the transition to a net-zero environment. The company boasts a skilled technical team with diverse expertise to drive its research and development efforts.

Jemstep

Acquisition in 2016

Jemstep Inc. offers online investment guidance and management services tailored for individual investors and financial advisors. Founded in 2008 and headquartered in Los Altos, California, the company leverages technology to provide ratings and comprehensive information on mutual funds and ETFs, including performance analysis and asset allocation. Jemstep's platform, Jemstep Advisor Pro, enhances the operations of investment advisors by automating client engagement, onboarding, and service processes, enabling them to attract more clients and manage assets more efficiently. The platform integrates with various service providers, allowing for a customizable business system that supports advisors in delivering enhanced value to their clients.

Gelesis

Private Equity Round in 2015

Gelesis, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for gastrointestinal-related chronic diseases, particularly obesity and its associated conditions. The company utilizes a mechanobiology technology platform to create its lead product, Gelesis100, an orally administered smart pill that contains hydrogel particles. This product is designed to expand in the stomach, promoting a feeling of fullness and aiding in weight management. Gelesis also offers PLENITY, an FDA-cleared product that assists individuals with weight management. In addition to these offerings, Gelesis has a pipeline of potential therapeutics targeting conditions such as Type 2 diabetes, non-alcoholic fatty liver disease, and chronic idiopathic constipation. Established in 2006, Gelesis aims to provide safe and effective solutions for patients dealing with obesity and related health issues.

Lamellar Biomedical

Venture Round in 2015

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that leverage mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic product designed to replicate the functions of lamellar bodies, primarily targeting respiratory diseases such as cystic fibrosis, as well as conditions like dry eye disease and radiotherapy-induced xerostomia. Established in June 2007, Lamellar Biomedical acquired the intellectual property rights to this innovative technology, which aims to improve treatment outcomes through anti-infective properties that enhance antibiotic efficacy and facilitate the delivery of genetic material for pulmonary disease therapies. The company's efforts are directed towards providing transformative solutions for complex and rare respiratory conditions.

Mereo Biopharma

Private Equity Round in 2015

Mereo Biopharma, based in London and founded in 2015, specializes in developing and commercializing innovative therapeutics for rare diseases and cancer. The company addresses the challenges faced by large pharmaceutical firms in resource allocation for drug development, particularly for candidates beyond Phase 2 trials. Mereo has acquired a mid-late stage portfolio of three well-characterized products from Novartis Pharmaceuticals, each backed by robust pre-clinical and proof-of-concept clinical data. The company focuses on transforming patient outcomes through its pipeline of drugs targeting significant unmet medical needs. Mereo leverages its team's expertise in selecting and advancing product opportunities and collaborates with ICON, a leading global contract research organization, to enhance its operational efficiency. Mereo aims to progress its products through critical development milestones before considering partnerships or commercialization, particularly in orphan disease indications.

Akamis Bio

Series C in 2015

Akamis Bio is a clinical-stage oncology company dedicated to improving the lives of cancer patients through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company is focused on developing a range of therapeutics aimed at solid tumors, utilizing its proprietary T-SIGn virus platform administered intravenously. This approach aims to enhance the ability of a patient's immune system to identify, attack, and eliminate cancer cells, providing a targeted treatment option for those affected by cancer.

SciFluor Life Sciences

Series B in 2015

SciFluor Life Sciences, Inc. is a drug discovery company based in Cambridge, Massachusetts, founded in 2011. The company focuses on developing therapeutics for various diseases, with a pipeline that includes small molecule compounds targeting areas such as neurology, ophthalmology, fibrosis, and inflammation. Notable products in development include SF0166, an integrin antagonist aimed at treating retinal diseases like age-related macular degeneration and diabetic macular edema through topical eye administration, and SF0034, a KCNQ2/3 activator designed to suppress neuronal hyperexcitability as an anti-epileptic treatment for partial-onset epilepsy. SciFluor utilizes a proprietary late-stage fluorination technology, licensed exclusively from Harvard University, which enhances drug properties such as metabolic stability, potency, bioavailability, and blood-brain-barrier penetration, allowing for fluorination of a wide array of organic compounds.

Luminex Trading & Analytics

Venture Round in 2015

Luminex Trading & Analytics develops an equity trading platform that facilitates access to clean, natural block liquidity at reduced trading costs. By exclusively engaging with venue-approved participants, the platform ensures low-cost trading while minimizing information leakage. This design enables traders to execute large block trades with decreased market impact, enhancing efficiency in the trading process.

SpaceX

Series G in 2015

SpaceX, officially known as Space Exploration Technologies, is a space transportation company founded in 2002 by Elon Musk and headquartered in Hawthorne, California. The company specializes in the design, manufacture, and launch of advanced rockets and spacecraft, including notable vehicles such as Falcon Heavy, Dragon, and Starship. SpaceX develops a range of technologies including crew and cargo capsules, rocket engines, and avionics, alongside guidance and control software. A key focus of SpaceX is the creation of partially reusable launch vehicles, such as Falcon 1 and Falcon 9, which aim to reduce the costs associated with space travel. By enabling the transport of cargo, humans, and payloads into space, SpaceX seeks to advance the capabilities and affordability of space exploration and travel.

Genomics

Series A in 2014

Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.

Kuur Therapeutics

Series B in 2014

Kuur Therapeutics Limited is a biopharmaceutical company focused on developing, manufacturing, and commercializing CAR-NKT cell immunotherapies for cancer treatment. The company is advancing a pipeline of immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics specializes in engineered off-the-shelf CAR-NKT cell therapies that leverage the natural biology of a specific subset of cytotoxic T cells known as natural killer T cells. This innovative approach aims to provide effective treatment options for a wide range of solid and hematological tumors. The company conducts clinical trials to demonstrate the efficacy of its CAR-NKT cell products, thereby striving to transform cancer care. Founded in 2005 and based in London, Kuur Therapeutics was previously known as Cell Medica Limited before its rebranding in February 2020.

Generator Hostels

Private Equity Round in 2014

Generator Hostel owns and operates a network of hostels across Europe and the United States, catering to a diverse range of travelers. The company offers various accommodation options, including shared dormitories and private en-suite rooms, ensuring flexibility for different preferences and budgets. In addition to sleeping arrangements, Generator Hostel features communal areas for relaxation, as well as bars and cafes that enhance the guest experience. The focus on providing comfortable and social environments makes Generator Hostel a popular choice among travelers seeking both affordability and quality in their lodging.

Alkermes

Post in 2014

Alkermes, Inc. is an integrated biotechnology company focused on developing, manufacturing, and commercializing medicines for chronic diseases. The company specializes in therapeutic areas such as central nervous system disorders, addiction, diabetes, and autoimmune disorders. Alkermes' key products include VIVITROL, an extended-release formulation of naltrexone used for treating alcohol dependence, and RISPERDAL CONSTA, an injectable medication for schizophrenia and bipolar I disorder. The company operates a research facility in Massachusetts and a commercial manufacturing facility in Ohio. Alkermes employs its proprietary technologies to create pharmaceutical products that address unmet medical needs, and it collaborates with third-party partners to enhance its product development efforts. With a significant presence in the United States, Alkermes also extends its operations to Ireland and other international markets.

Ensurge Micropower

Post in 2013

Ensurge Micropower specializes in developing ultrathin, flexible, and safe energy storage solutions, primarily for wearable devices and connected sensors. The company utilizes innovative solid-state lithium battery (SSLB) technology, which allows for the creation of powerful, lightweight, and cost-effective rechargeable batteries suitable for a variety of applications. Ensurge operates a state-of-the-art flexible electronics manufacturing facility in Silicon Valley, where it employs patented process technology and materials in conjunction with roll-to-roll production methods to maximize the benefits of its SSLB technology. With corporate headquarters in Oslo and global headquarters in San Jose, Ensurge Micropower is focused on delivering advanced energy storage solutions to both established and emerging markets.

PolyTherics

Venture Round in 2013

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

infirst Healthcare

Series A in 2013

infirst Healthcare Ltd. is a consumer healthcare company based in London, United Kingdom, founded in 2012. The company specializes in developing innovative versions of established over-the-counter medicines, focusing on solutions that can be launched within a 12-36 month timeframe. Notably, infirst has created a cocoa-flavored medicine aimed at treating cough and cold symptoms. As a spin-out from the UK-based drug discovery group SEEK, infirst leverages its intellectual property to develop breakthrough treatments for significant health issues. The company is led by CEO Manfred Scheske, who has extensive experience in the consumer healthcare sector, having previously overseen GSK's European Consumer Healthcare division and its North American operations.

Xeros

Venture Round in 2013

Xeros Ltd. is a new company focused on the development of "virtually waterless" laundry cleaning. Harnessing over 30 years of research by Professor Stephen Burkinshaw and the University of Leeds, Xeros is the brand name for a patented polymer based cleaning that creates step change advantage in the cost and environmental impact of aqueous wash cleaning.

Glide Pharmaceutical

Venture Round in 2013

Glide Pharmaceutical Technologies is a clinical stage development company that specializes in the creation of solid dose formulations for therapeutics and vaccines. The company is known for its innovative solid dose injector system, which aims to enhance patient compliance in self-administering long-term therapies. Glide's product pipeline features formulations for various medications, including octreotide, teriparatide, and vaccines for anthrax and influenza. The company's focus on needle-free injection methods seeks to improve the treatment experience for both patients and healthcare providers. Formerly known as Caretek Medical, Glide Pharmaceutical is dedicated to advancing healthcare through its unique delivery systems.

Lamellar Biomedical

Series A in 2013

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that leverage mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic product designed to replicate the functions of lamellar bodies, primarily targeting respiratory diseases such as cystic fibrosis, as well as conditions like dry eye disease and radiotherapy-induced xerostomia. Established in June 2007, Lamellar Biomedical acquired the intellectual property rights to this innovative technology, which aims to improve treatment outcomes through anti-infective properties that enhance antibiotic efficacy and facilitate the delivery of genetic material for pulmonary disease therapies. The company's efforts are directed towards providing transformative solutions for complex and rare respiratory conditions.

Kuur Therapeutics

Venture Round in 2012

Kuur Therapeutics Limited is a biopharmaceutical company focused on developing, manufacturing, and commercializing CAR-NKT cell immunotherapies for cancer treatment. The company is advancing a pipeline of immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics specializes in engineered off-the-shelf CAR-NKT cell therapies that leverage the natural biology of a specific subset of cytotoxic T cells known as natural killer T cells. This innovative approach aims to provide effective treatment options for a wide range of solid and hematological tumors. The company conducts clinical trials to demonstrate the efficacy of its CAR-NKT cell products, thereby striving to transform cancer care. Founded in 2005 and based in London, Kuur Therapeutics was previously known as Cell Medica Limited before its rebranding in February 2020.

Akamis Bio

Series B in 2012

Akamis Bio is a clinical-stage oncology company dedicated to improving the lives of cancer patients through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company is focused on developing a range of therapeutics aimed at solid tumors, utilizing its proprietary T-SIGn virus platform administered intravenously. This approach aims to enhance the ability of a patient's immune system to identify, attack, and eliminate cancer cells, providing a targeted treatment option for those affected by cancer.

Oxford Immunotec

Venture Round in 2012

Oxford Immunotec Limited is a medical diagnostics company that specializes in the development and commercialization of innovative tests for infectious and immunological diseases, leveraging its patented T-SPOT technology. This technology enables the measurement of T cell responses at a single-cell level, which aids in the diagnosis, prognosis, and monitoring of conditions regulated by the immune system. The company offers the T-SPOT.TB test, a cellular blood test designed to detect both active and latent tuberculosis infections. Additionally, it operates testing laboratories in the United States and the United Kingdom, providing access to various immunological tests for healthcare providers. Founded in 2002 and headquartered in Abingdon, United Kingdom, with operations in Marlborough, Massachusetts, Oxford Immunotec Limited serves a diverse clientele, including independent laboratories, hospital systems, and public and private institutions across the United States and internationally.

Oxford Nanopore Technologies

Venture Round in 2012

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

Spin Memory

Series A in 2012

Spin Memory, Inc. specializes in the development of spin-transfer torque magnetoresistive random access memory (STT-MRAM) technologies and products. Founded in 2007 and headquartered in Fremont, California, the company aims to address the scaling and power challenges faced by memory devices. By providing solutions that replace on-chip SRAM and various non-volatile memories in both embedded and stand-alone applications, Spin Memory enhances speed, power efficiency, and endurance. The underlying technology, known as orthogonal spin transfer MRAM, was initially developed through a collaboration between Allied Minds and New York University, with significant contributions from Professor Andrew Kent. Spin Memory's innovations lead to faster switching times and lower power consumption, without the endurance and data retention limitations found in other implementations of STT-MRAM.

Centrify

Series D in 2011

Centrify Corporation specializes in unified identity management software tailored for cloud, mobile, and data center environments. The company operates the Centrify Identity Platform, which focuses on enhancing enterprise security by addressing cyberthreats and data breaches at their source. Its offerings include Identity-as-a-Service for cloud and mobile applications, privileged identity management solutions, multi-factor authentication, and a developer program. Centrify Identity Service enhances productivity and secures access to various applications through single sign-on and user provisioning. Additionally, the Centrify Privilege Service manages and audits access for internal users and third-party vendors, while the Centrify Server Suite consolidates identity and privilege management. The company serves a diverse clientele, including Fortune 500 companies, financial institutions, and federal agencies. Founded in 2004 and based in Santa Clara, California, Centrify merged with Thycotic in 2021 and rebranded as Delinea, Inc. in 2022, further solidifying its position as a leader in both Privileged Identity Management and Identity-as-a-Service.

Nexeon

Series C in 2011

Nexeon Limited is a developer and manufacturer of advanced silicon-based anode materials for rechargeable lithium-ion batteries. Founded in 2006 and headquartered in Abingdon, United Kingdom, with an additional office in Yokohama, Japan, the company focuses on creating innovative battery materials that enhance energy density and capacity. These improvements allow for the production of lighter, more powerful batteries that can support a variety of applications, including consumer electronics, electric vehicles, sustainable energy, aerospace, medical, and defense industries. By enabling longer battery life and faster charging times, Nexeon's technology plays a crucial role in advancing sustainable energy solutions and supporting the transition to a net-zero environment. The company boasts a skilled technical team with diverse expertise to drive its research and development efforts.

Oxford Nanopore Technologies

Venture Round in 2011

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

Circassia

Series D in 2011

Circassia Group Plc is a specialty pharmaceutical company based in Oxford, United Kingdom, that specializes in the development and commercialization of respiratory products. The company operates through three main segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. Circassia markets NIOX and NIOX VERO, products designed for asthma diagnosis and management, and offers Tudorza and Duaklir for the treatment of COPD. The latter is a fixed-dose combination inhaler that delivers medication for COPD maintenance. Additionally, Circassia is advancing LungFit, a portable system that generates precise amounts of nitric oxide for therapeutic use. The company sells its products directly to specialists in several countries, including the United States, United Kingdom, China, Italy, and Germany, as well as through international partners. Circassia has a collaboration with AstraZeneca for the promotion of Tudorza and Duaklir, along with U.S. and Chinese commercial rights to LungFit. Founded in 2006, Circassia Group Plc was formerly known as Circassia Pharmaceuticals plc until its name change in May 2020.

MaxWest Environmental Systems

Series C in 2011

MaxWest Environmental Systems specializes in developing and operating waste-to-energy gasification facilities. The company utilizes a gasification and heat integration process to convert various types of waste, including biosolids, agricultural residues, construction and demolition debris, waste plastics, sludge, and wood waste, into renewable green energy. By transforming carbon-based products into usable energy, MaxWest aims to contribute to sustainable waste management solutions while providing an alternative energy source.

Akamis Bio

Series A in 2010

Akamis Bio is a clinical-stage oncology company dedicated to improving the lives of cancer patients through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company is focused on developing a range of therapeutics aimed at solid tumors, utilizing its proprietary T-SIGn virus platform administered intravenously. This approach aims to enhance the ability of a patient's immune system to identify, attack, and eliminate cancer cells, providing a targeted treatment option for those affected by cancer.

Oxford Nanopore Technologies

Series C in 2010

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

Circassia

Series C in 2009

Circassia Group Plc is a specialty pharmaceutical company based in Oxford, United Kingdom, that specializes in the development and commercialization of respiratory products. The company operates through three main segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. Circassia markets NIOX and NIOX VERO, products designed for asthma diagnosis and management, and offers Tudorza and Duaklir for the treatment of COPD. The latter is a fixed-dose combination inhaler that delivers medication for COPD maintenance. Additionally, Circassia is advancing LungFit, a portable system that generates precise amounts of nitric oxide for therapeutic use. The company sells its products directly to specialists in several countries, including the United States, United Kingdom, China, Italy, and Germany, as well as through international partners. Circassia has a collaboration with AstraZeneca for the promotion of Tudorza and Duaklir, along with U.S. and Chinese commercial rights to LungFit. Founded in 2006, Circassia Group Plc was formerly known as Circassia Pharmaceuticals plc until its name change in May 2020.

Chelsio Communications

Series F in 2009

Chelsio Communications, Inc. is a technology company that specializes in high-performance networking and storage solutions. Founded in 1997 and headquartered in Sunnyvale, California, with a design center in Bengaluru, India, Chelsio develops both hardware and software to address the demands of virtualized enterprise data centers, cloud service installations, and cluster computing environments. Its product offerings include Unified Wire Ethernet network adapter cards, unified storage software, high-performance storage gateways, unified management software, and bypass cards, among others. The company also provides protocol engines and server adapters designed for convergence networks, facilitating efficient traffic management over Ethernet. Chelsio markets its products through a network of distributors, integrators, and resellers, serving customers both domestically and internationally.

Barosense

Series D in 2009

BaroSense is focused on developing and commercializing innovative medical devices aimed at addressing obesity, a significant healthcare challenge in the United States. The company aims to provide safe, simple, and effective alternatives to surgical treatments for obesity, catering to individuals who require assistance beyond traditional dieting methods and wish to avoid extensive and irreversible surgical options. BaroSense's product offerings include minimally invasive therapeutic procedures and devices, such as a trans-oral endoscopic restrictive implant system, designed to facilitate weight loss in a less invasive manner.

LogLogic

Series D in 2009

LogLogic is a provider of a scalable log and security intelligence platform designed for enterprises and cloud environments. The company serves over 1,300 customers, offering solutions that enable the collection and analysis of vast amounts of data generated by IT assets. LogLogic's platform equips security, IT operations, and compliance professionals with actionable insights to proactively identify issues, make informed decisions, and ensure compliance with various regulations. By managing over 1,000 petabytes of data, LogLogic enhances network stability and security, giving administrators immediate visibility into network activities and translating raw data into meaningful information.

ConSentry Networks

Venture Round in 2009

ConSentry Networks is leading the delivery of intelligent control. Customers around the globe have adopted their intelligent control, enabling them to capitalize on today's new business practices including using contractors, outsourcing and offshoring, and more rapidly establishing working partnerships. ConSentry Networks, Inc. was founded in 2003 and is based in Milpitas, California. The company has received funding from Accel Partners, DAG Ventures, INVESCO Private Capital, and Translink Capital.

NovaSys

Venture Round in 2008

NovaSys Health is a prominent provider of managed healthcare services, operating one of the largest health plans in Arkansas. With approximately 11,000 contracted providers in the region and over 4,300 in Arkansas, the company emphasizes strong relationships with healthcare providers. It offers a range of health plans and related services, including customized solutions, provider relations, and eligibility and billing administration, catering to a diverse network of hospitals, physicians, and ancillary providers.

NOVASYS MEDICAL

Series D in 2008

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Touchdown Technologies

Series D in 2008

Touchdown Technologies, Inc. specializes in the design, manufacture, and support of advanced Micro-Electro-Mechanical Systems (MEMS) probe cards. The company offers products such as the ACCU-TORQ probe, a torsional contactor, and GIGA-TORQ probe cards specifically for DRAM applications. These products are tailored to meet the production wafer test requirements of semiconductor manufacturers globally. Founded in 2003 and based in Baldwin Park, California, Touchdown Technologies aims to reduce wafer test costs through innovative technologies that enhance the efficiency of highly parallel probe cards.

Circassia

Series B in 2008

Circassia Group Plc is a specialty pharmaceutical company based in Oxford, United Kingdom, that specializes in the development and commercialization of respiratory products. The company operates through three main segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. Circassia markets NIOX and NIOX VERO, products designed for asthma diagnosis and management, and offers Tudorza and Duaklir for the treatment of COPD. The latter is a fixed-dose combination inhaler that delivers medication for COPD maintenance. Additionally, Circassia is advancing LungFit, a portable system that generates precise amounts of nitric oxide for therapeutic use. The company sells its products directly to specialists in several countries, including the United States, United Kingdom, China, Italy, and Germany, as well as through international partners. Circassia has a collaboration with AstraZeneca for the promotion of Tudorza and Duaklir, along with U.S. and Chinese commercial rights to LungFit. Founded in 2006, Circassia Group Plc was formerly known as Circassia Pharmaceuticals plc until its name change in May 2020.

Chelsio Communications

Series E in 2008

Chelsio Communications, Inc. is a technology company that specializes in high-performance networking and storage solutions. Founded in 1997 and headquartered in Sunnyvale, California, with a design center in Bengaluru, India, Chelsio develops both hardware and software to address the demands of virtualized enterprise data centers, cloud service installations, and cluster computing environments. Its product offerings include Unified Wire Ethernet network adapter cards, unified storage software, high-performance storage gateways, unified management software, and bypass cards, among others. The company also provides protocol engines and server adapters designed for convergence networks, facilitating efficient traffic management over Ethernet. Chelsio markets its products through a network of distributors, integrators, and resellers, serving customers both domestically and internationally.

POINT Biomedical

Private Equity Round in 2008

POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphereâ„¢. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphereâ„¢, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques

Barosense

Series C in 2007

BaroSense is focused on developing and commercializing innovative medical devices aimed at addressing obesity, a significant healthcare challenge in the United States. The company aims to provide safe, simple, and effective alternatives to surgical treatments for obesity, catering to individuals who require assistance beyond traditional dieting methods and wish to avoid extensive and irreversible surgical options. BaroSense's product offerings include minimally invasive therapeutic procedures and devices, such as a trans-oral endoscopic restrictive implant system, designed to facilitate weight loss in a less invasive manner.

Cast Iron Systems

Series F in 2007

Cast Iron Systems, Inc. specializes in providing software-as-a-service integration appliances tailored for large and midsize companies. The company offers the iA3000 application integration appliance, which delivers network computing solutions and preconfigured options for both enterprise and on-demand applications. These solutions enable users to connect with specific applications and facilitate integration processes, particularly for SAP and Oracle systems. In addition to its hardware and software offerings, Cast Iron Systems provides consulting, technical support, and educational services to enhance user experience and operational efficiency. Founded in 2001 and based in Mountain View, California, the company was previously known as IronHide Corporation.

AccountNow

Series C in 2007

AccountNow is a prominent provider of prepaid card financial solutions, catering to the 40 million consumers in the United States who lack established credit or traditional banking relationships. The company offers an alternative to conventional checking accounts, allowing users to access financial and payment systems through its prepaid Visa and MasterCard cards. AccountNow’s services include online bill payment, card-to-card transfers, and FDIC-insured deposits, enabling customers to deposit paychecks directly and make purchases wherever Visa debit or MasterCard is accepted. The prepaid cards are issued by The Bancorp Bank or MetaBank, ensuring secure and reliable financial services for individuals seeking accessible banking alternatives.

Antenova

Venture Round in 2007

Antenova Ltd specializes in the design, development, and supply of standard and custom antennas, as well as radio frequency antenna modules for a variety of applications. The company's products cater to the wireless machine-to-machine (M2M) and Internet of Things (IoT) sectors, along with consumer electronic devices. Antenova's offerings include specialized antennas for WLAN, Wi-Fi, GPS, and telecom applications, and encompass various product lines such as gigaNOVA, RADIONOVA, and ceriiANT. The company also provides integration services, antenna matching and testing, and custom antenna design alongside sales and technical support. Antenova's solutions are utilized across diverse sectors, including automotive, healthcare, wearables, industrial, and smart city technologies. Established in 1999, the company is headquartered in Hatfield, United Kingdom, with design and sales centers in Taipei, Chicago, and Shanghai, and manufacturing operations in Taiwan and China. Its products are distributed through a global network of distributors.

Centrify

Series C in 2007

Centrify Corporation specializes in unified identity management software tailored for cloud, mobile, and data center environments. The company operates the Centrify Identity Platform, which focuses on enhancing enterprise security by addressing cyberthreats and data breaches at their source. Its offerings include Identity-as-a-Service for cloud and mobile applications, privileged identity management solutions, multi-factor authentication, and a developer program. Centrify Identity Service enhances productivity and secures access to various applications through single sign-on and user provisioning. Additionally, the Centrify Privilege Service manages and audits access for internal users and third-party vendors, while the Centrify Server Suite consolidates identity and privilege management. The company serves a diverse clientele, including Fortune 500 companies, financial institutions, and federal agencies. Founded in 2004 and based in Santa Clara, California, Centrify merged with Thycotic in 2021 and rebranded as Delinea, Inc. in 2022, further solidifying its position as a leader in both Privileged Identity Management and Identity-as-a-Service.

Celoxica

Venture Round in 2007

Based in London, United Kingdom, Celoxica delivers latency market data access and order execution solutions to the advanced trading community. The company’s solutions include a full range of market data feed handlers for the main U.S. and European equities, options, futures exchanges, and FX. With clients that include trading firms who co-locate their strategic applications in high frequency trading environments, market making, liquidity provision, algorithmic trading, and smart order routing, the company also offers a single access point for brokers and their clients by handling inbound FIX, credit check, and outbound native protocol to the execution venues. Celoxica was founded in 1996.

Cortina Systems

Series D in 2006

Cortina Systems is a prominent supplier of intelligent communication solutions, specializing in advanced port processing and connectivity across various market segments, including Core, Metro, Access, and Enterprise. The company focuses on delivering high-speed analog-digital integration through a diverse range of products that cater to the performance, density, and flexibility needs of its customers. By emphasizing collaboration with clients to understand their system requirements, Cortina Systems aims to anticipate future needs and foster the development of new generations of services. Its innovative semiconductor technology enables effective network connectivity and bandwidth delivery from core networks to home networks, facilitating faster market entry and enhancing revenue opportunities for its clients.

LipoScience

Series F in 2006

LipoScience, based in Raleigh, North Carolina, specializes in developing in vitro diagnostic tests utilizing nuclear magnetic resonance (NMR) technology. The company's flagship product, the NMR LipoProfile test, quantifies low density lipoprotein particles (LDL-P) in blood samples, offering crucial insights for physicians and patients to tailor heart disease risk management. With more than 8 million tests ordered, LipoScience is at the forefront of personalized diagnostics, providing actionable data that enhances patient care and treatment strategies.

ConSentry Networks

Series D in 2006

ConSentry Networks is leading the delivery of intelligent control. Customers around the globe have adopted their intelligent control, enabling them to capitalize on today's new business practices including using contractors, outsourcing and offshoring, and more rapidly establishing working partnerships. ConSentry Networks, Inc. was founded in 2003 and is based in Milpitas, California. The company has received funding from Accel Partners, DAG Ventures, INVESCO Private Capital, and Translink Capital.

Cast Iron Systems

Series E in 2006

Cast Iron Systems, Inc. specializes in providing software-as-a-service integration appliances tailored for large and midsize companies. The company offers the iA3000 application integration appliance, which delivers network computing solutions and preconfigured options for both enterprise and on-demand applications. These solutions enable users to connect with specific applications and facilitate integration processes, particularly for SAP and Oracle systems. In addition to its hardware and software offerings, Cast Iron Systems provides consulting, technical support, and educational services to enhance user experience and operational efficiency. Founded in 2001 and based in Mountain View, California, the company was previously known as IronHide Corporation.

Xenon Pharmaceuticals

Private Equity Round in 2006

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, focused on developing therapeutics for neurological disorders. The company's clinical pipeline includes several product candidates aimed at treating epilepsy, such as XEN496 and XEN1101, both Kv7 potassium channel modulators currently in Phase II trials, and XEN901, a selective Nav1.6 sodium channel inhibitor in Phase I trials. Additionally, Xenon is developing XEN007, a central nervous system-acting calcium channel modulator, also in Phase I trials. The company leverages insights from genetic research, particularly from families with severe phenotypes, to identify drug targets, which may extend beyond rare genetic disorders. Furthermore, Xenon has established a collaboration with Neurocrine Biosciences to advance the development of innovative epilepsy treatments.

Touchdown Technologies

Series B in 2005

Touchdown Technologies, Inc. specializes in the design, manufacture, and support of advanced Micro-Electro-Mechanical Systems (MEMS) probe cards. The company offers products such as the ACCU-TORQ probe, a torsional contactor, and GIGA-TORQ probe cards specifically for DRAM applications. These products are tailored to meet the production wafer test requirements of semiconductor manufacturers globally. Founded in 2003 and based in Baldwin Park, California, Touchdown Technologies aims to reduce wafer test costs through innovative technologies that enhance the efficiency of highly parallel probe cards.

Celoxica

Venture Round in 2005

Based in London, United Kingdom, Celoxica delivers latency market data access and order execution solutions to the advanced trading community. The company’s solutions include a full range of market data feed handlers for the main U.S. and European equities, options, futures exchanges, and FX. With clients that include trading firms who co-locate their strategic applications in high frequency trading environments, market making, liquidity provision, algorithmic trading, and smart order routing, the company also offers a single access point for brokers and their clients by handling inbound FIX, credit check, and outbound native protocol to the execution venues. Celoxica was founded in 1996.

Cortina Systems

Series C in 2005

Cortina Systems is a prominent supplier of intelligent communication solutions, specializing in advanced port processing and connectivity across various market segments, including Core, Metro, Access, and Enterprise. The company focuses on delivering high-speed analog-digital integration through a diverse range of products that cater to the performance, density, and flexibility needs of its customers. By emphasizing collaboration with clients to understand their system requirements, Cortina Systems aims to anticipate future needs and foster the development of new generations of services. Its innovative semiconductor technology enables effective network connectivity and bandwidth delivery from core networks to home networks, facilitating faster market entry and enhancing revenue opportunities for its clients.

Centrify

Series B in 2005

Centrify Corporation specializes in unified identity management software tailored for cloud, mobile, and data center environments. The company operates the Centrify Identity Platform, which focuses on enhancing enterprise security by addressing cyberthreats and data breaches at their source. Its offerings include Identity-as-a-Service for cloud and mobile applications, privileged identity management solutions, multi-factor authentication, and a developer program. Centrify Identity Service enhances productivity and secures access to various applications through single sign-on and user provisioning. Additionally, the Centrify Privilege Service manages and audits access for internal users and third-party vendors, while the Centrify Server Suite consolidates identity and privilege management. The company serves a diverse clientele, including Fortune 500 companies, financial institutions, and federal agencies. Founded in 2004 and based in Santa Clara, California, Centrify merged with Thycotic in 2021 and rebranded as Delinea, Inc. in 2022, further solidifying its position as a leader in both Privileged Identity Management and Identity-as-a-Service.

ConSentry Networks

Series C in 2005

ConSentry Networks is leading the delivery of intelligent control. Customers around the globe have adopted their intelligent control, enabling them to capitalize on today's new business practices including using contractors, outsourcing and offshoring, and more rapidly establishing working partnerships. ConSentry Networks, Inc. was founded in 2003 and is based in Milpitas, California. The company has received funding from Accel Partners, DAG Ventures, INVESCO Private Capital, and Translink Capital.

SkyPilot Networks

Series C in 2005

SkyPilot Networks is a prominent provider of broadband wireless equipment designed for service providers, municipalities, and public safety agencies to efficiently deploy various network services. These services include last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. The company's innovative solution employs a patented multi-hop point-to-multipoint architecture that enhances reach, reduces interference, and optimizes spectral efficiency. This technology results in a scalable, reliable, and deterministic broadband wireless network that simplifies design, increases deployment flexibility, and lowers both equipment and operational costs. SkyPilot's products include the SkyPilot Connector Mini and Pro, which offer cost-effective customer premises equipment for long-range connectivity, and the SkyPilot EMS, an element management system that aids in the deployment and management of wireless mesh networks. With a proven track record, SkyPilot has delivered its systems to customers in over 50 countries and is headquartered in Santa Clara, California.

Arcot Systems

Series A in 2005

Arcot Systems, Inc. specializes in authentication and digital signing solutions aimed at protecting and verifying the digital identities of cardholders and merchants. Founded in 1997 and headquartered in Sunnyvale, California, with a technology center in Bangalore, India, the company offers a variety of services, including consumer portal protection, FFIEC compliance, identity management, Internet threat protection, SAFE biopharmaceutical compliance, and VPN authentication. Its key products include TransFort for Issuers and Merchants, RiskFort for real-time fraud prevention, WebFort and ArcotID for software-based authentication, A-OK On-Demand for secure authentication processes, and SignFort to streamline document signing and approval. Arcot Systems serves financial institutions, pharmaceutical companies, and e-commerce platforms, helping them combat online fraud and identity theft.

Cast Iron Systems

Series D in 2005

Cast Iron Systems, Inc. specializes in providing software-as-a-service integration appliances tailored for large and midsize companies. The company offers the iA3000 application integration appliance, which delivers network computing solutions and preconfigured options for both enterprise and on-demand applications. These solutions enable users to connect with specific applications and facilitate integration processes, particularly for SAP and Oracle systems. In addition to its hardware and software offerings, Cast Iron Systems provides consulting, technical support, and educational services to enhance user experience and operational efficiency. Founded in 2001 and based in Mountain View, California, the company was previously known as IronHide Corporation.

Genband

Venture Round in 2005

GENBAND is a global supplier of IP gateways, session border controllers, and FMC security solutions that enhance the performance and security of fixed and mobile communication networks. The company specializes in developing IP multimedia applications and infrastructure products aimed at transforming the speed and quality of communication. GENBAND's software solutions facilitate seamless connectivity and rapid deployment of services for service providers, enterprises, and systems integrators. By integrating real-time contextual communications into business and consumer applications, GENBAND aims to improve productivity and user engagement across various workflows.

WhereNet

Venture Round in 2005

WhereNet Corporation specializes in wireless solutions for tracking and managing enterprise assets. The company offers an integrated wireless infrastructure that supports real-time location, messaging, and telemetry applications. Key products include WhereLAN, a cellular network of locating access points; WhereTag, a line of low-powered active radio frequency transmitters; and WhereCall, a wireless messaging system for parts replenishment in industrial manufacturing. Additionally, WhereNet provides software development tools through its Visibility Software Server, facilitating integration with customer and third-party applications. Founded in 1997 and headquartered in Santa Clara, California, WhereNet operates as a subsidiary of Zebra Technologies Corp. The company's solutions are designed to help customers improve operational efficiency, enhance asset returns, and reduce costs, ultimately leading to better customer service.

NOVASYS MEDICAL

Series C in 2004

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Confluent Photonics

Series B in 2003

Confluent Photonics Corporation is developing passive and active DWDM optical components for the telecommunications industry based on silicon-on-insulator (SOI) semiconductor fabrication techniques. The use of SOI along with the CMOS fabrication infrastructure developed to process SOI enables cost-effective high volume optical telecom component solutions for the access, metropolitan and long haul telecom markets. The compatibility of Confluent optical designs and manufacturing techniques with CMOS fabrication also provides a pathway for the future integration of optics and electronics on the same telecommunications chip. Current optical telecommunication product technologies and designs result in miniaturized optical lab benches lacking thermal and mechanical robustness. In contrast, Confluent is designing and fabricating Telcordia-compliant optical chip components for the automated manufacture of integrated optical circuits. These components are designed to be insensitive to their environment. Using semiconductor-manufacturing techniques provides built in optical alignment, high volume production and low cost.

LipoScience

Series E in 2003

LipoScience, based in Raleigh, North Carolina, specializes in developing in vitro diagnostic tests utilizing nuclear magnetic resonance (NMR) technology. The company's flagship product, the NMR LipoProfile test, quantifies low density lipoprotein particles (LDL-P) in blood samples, offering crucial insights for physicians and patients to tailor heart disease risk management. With more than 8 million tests ordered, LipoScience is at the forefront of personalized diagnostics, providing actionable data that enhances patient care and treatment strategies.

VIEO

Series B in 2003

VIEO provides innovative application service level management solutions for ensuring business certainty. These solutions provide end-to-end visibility of Microsoft web-based and Citrix-based application infrastructures and pinpoint resource problems that impact service levels. Using VIEO solutions, IT organizations can improve service delivery while reducing costs and complexity. VIEO's awards include Computerworld's 2004 Innovative Technology Award and InfoWorld's 2004 Systems Management Product of the Year. Led by IT visionary and successful serial entrepreneur Bob Fabbio, VIEO is headquartered in Austin, Texas.

SkyPilot Networks

Series B in 2001

SkyPilot Networks is a prominent provider of broadband wireless equipment designed for service providers, municipalities, and public safety agencies to efficiently deploy various network services. These services include last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. The company's innovative solution employs a patented multi-hop point-to-multipoint architecture that enhances reach, reduces interference, and optimizes spectral efficiency. This technology results in a scalable, reliable, and deterministic broadband wireless network that simplifies design, increases deployment flexibility, and lowers both equipment and operational costs. SkyPilot's products include the SkyPilot Connector Mini and Pro, which offer cost-effective customer premises equipment for long-range connectivity, and the SkyPilot EMS, an element management system that aids in the deployment and management of wireless mesh networks. With a proven track record, SkyPilot has delivered its systems to customers in over 50 countries and is headquartered in Santa Clara, California.

Starvox Communications

Series D in 2001

StarVOX is a provider of facilities-based wholesale and retail voice services, specializing in enhanced VoIP solutions. The company offers a domestic VoIP network with multiple points of presence, enabling seamless voice communication integrated with written communication through a desktop application. Additionally, StarVOX provides real-time reports and statistics to support established and emerging carriers, ensuring reliable and cost-effective global connectivity. Its products are marketed and serviced through major solution providers, notably in partnership with HP, where StarVOX's software is combined with HP's Open Call Multi Controller application platforms and Cisco Powered Network equipment. This collaboration results in a comprehensive, factory-integrated IP telephony solution tailored for service providers, capable of delivering a wide range of value-added services and upgrades.

Invesco

Top Sectors

Top Regions

Top Stages

Justin Leverenz

Chief Investment Officer, Developing Markets Equities

117 past transactions

Matalan

Asia Dragon Trust

Caredoc

Franklin Energy Services

Mynd

Flowcarbon

GeNeuro

Copper Banking

Capchase

Swiggy

Hum Capital

Pine Labs

Aumni

Abogen Biosciences

Mynd

Brii Biosciences

Godrej Garden City

Nubank

Expert.ai

Clarksons

intelliflo redblack

Grab

Evofem Biosciences

OppenheimerFunds

Intelliflo

Alfred

T She Dingzhi

Lamellar Biomedical

Source ETF

Glide Pharmaceutical

Vedanta Biosciences

Nexeon

Jemstep

Gelesis

Lamellar Biomedical

Mereo Biopharma

Akamis Bio

SciFluor Life Sciences

Luminex Trading & Analytics

SpaceX

Genomics

Kuur Therapeutics

Generator Hostels

Alkermes

Ensurge Micropower

PolyTherics

infirst Healthcare

Xeros

Glide Pharmaceutical

Lamellar Biomedical

Kuur Therapeutics

Akamis Bio

Oxford Immunotec

Oxford Nanopore Technologies

Spin Memory

Centrify

Nexeon

Oxford Nanopore Technologies

Circassia

MaxWest Environmental Systems

Akamis Bio

Oxford Nanopore Technologies

Circassia

Chelsio Communications

Barosense

LogLogic

ConSentry Networks

NovaSys

NOVASYS MEDICAL

Touchdown Technologies

Circassia

Chelsio Communications

POINT Biomedical